Latest news with #SeongsooPark
Korea Herald
2 days ago
- Business
- Korea Herald
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product.
Yahoo
2 days ago
- Business
- Yahoo
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech ABSalipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong PharmaceuticalDaewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd.
Yahoo
04-06-2025
- Business
- Yahoo
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
04-06-2025
- Business
- Yahoo
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
10-02-2025
- Business
- Zawya
Daewoong Pharmaceutical, a leading healthcare company in Korea, has launched its botulinum toxin product NABOTA in Saudi Arabia
SEOUL, South Korea and RIYADH, Saudi Arabia /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee), a leading healthcare company in Korea, announced the official launch of its high-purity, high-quality botulinum toxin product, NABOTA, in Saudi Arabia. The launch follows a rigorous quality evaluation process conducted by the Saudi Food and Drug Authority (SFDA). As recognized with approvals from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada, Daewoong Pharmaceutical's botulinum toxin has demonstrated outstanding quality and safety. This milestone is expected to serve as a key gateway for Daewoong Pharmaceutical's expansion into the Middle Eastern market. Leveraging NABOTA's superior quality and safety, Daewoong Pharmaceutical aims to meet the needs of patients in Saudi Arabia and the wider Middle Eastern region while expanding its market share. Daewoong Pharmaceutical's premium high-purity botulinum toxin, produced using the patented 'HI-PURE™ Technology' and advanced vacuum drying processes, received FDA approval in 2019, making it the first Asian-manufactured botulinum toxin to gain such recognition. NABOTA boasts a high-purity composition with over 98% of the 900kDa complex and ensures rapid and precise effect. Additionally, its drying process prevents the formation of ice nuclei, minimizing the formation of inactive toxins, which contributes to immunogenicity and ultimately, enhancing safety. NABOTA shares the same molecular structure (900kDa) as AbbVie's Botox, which holds the largest market share in Saudi Arabia, and has demonstrated equivalent(non-inferior) efficacy, positioning NABOTA for smooth transition and accelerated market adoption in the region. To commemorate the launch, Daewoong Pharmaceutical hosted a symposium on January 24 at the Fairmont Hotel in Riyadh, Saudi Arabia. The event gathered approximately 300 local healthcare professionals and featured Dr. Hassan Galadari, a key opinion leader in the region and dermatologist from the UAE. Dr. Galadari delivered a presentation titled 'CHANGE THE GAME Prabotulinum Toxin,' sharing global clinical results and treatment insights of NABOTA to local healthcare professionals. "NABOTA has the same protein molecular structure as Botox, at 900kDa, and has proven its efficacy and safety through clinical trials and regulatory approvals in advanced markets," said Dr. Galadari. "It stands out for its precision, longevity, and high patient satisfaction." Dr. Amr Abduljabbar, a Saudi Arabian dermatologist and symposium moderator, added, "This event allowed us to share valuable insights into NABOTA's advanced manufacturing process, superior quality, and global clinical data. I believe NABOTA will be a game-changer in Saudi Arabia, a key market within the Middle East and Africa botulinum toxin industry." Jun-soo Yun, Head of the NABOTA Business Unit at Daewoong Pharmaceutical, stated, "NABOTA is Korea's most exported botulinum toxin product, owing to its high purity and quality. Daewoong Pharmaceutical's botulinum toxin products are currently approved in 69 countries and partnered in over 80 countries. Saudi Arabia is the largest market in the Middle East, and with this launch, Daewoong Pharmaceutical will further strengthen its presence in the Middle East and Africa."
